Lexpert magazine features articles and columns on developments in legal practice management, deals and lawsuits of interest in Canada, the law and business issues of interest to legal professionals and businesses that purchase legal services.
Issue link: https://digital.carswellmedia.com/i/1547685
24 www.lexpert.ca Top 10 Business Decisions PHARMASCIENCE INC. V. JANSSEN INC., 2026 SCC 26 • Pharmascience Inc. > Goodmans LLP > Andrew Brodkin, Daniel Cappe, and Sandon Shogilev • Janssen Inc. and Janssen Pharmaceutica N.V. > Blake, Cassels & Graydon LLP; Fasken Martineau DuMoulin LLP; Belmore Neidrauer LLP > Catherine Beagan Flood, Fiona Legere, Spencer Livingstone, Julie Desrosiers, Marian Wolanski, and Eliane Elbogen • Canadian Generic Pharmaceutical Association > Osler, Hoskin & Harcourt LLP > J. Bradley White, Nathaniel Lipkus, and Daniel Hnatchuk • International Federation of Intellectual Property Attorneys > Cassels Brock & Blackwell LLP > Andrew Skodyn, Sean Jackson, and Eleanor Wilson • Innovative Medicines Canada and BIOTECanada > Norton Rose Fulbright Canada LLP > Orestes Pasparakis and Kristin Wall • Canadian Organization for Rare Disorders > Tyr LLP > Melanie Baird, Amy Grenon, Cole Meagher, and Nick Morrow • David Homuth, Marco Solmi, and Pierre Bleau > Gowling WLG (Canada) LLP > Christopher C. Van Barr, Erin Creber, Will Boyer, and Mackenzie Jamieson CLIENTS > FIRMS > LAWYERS CAN A pharmaceutical company patent a dosing regimen for a drug? The Supreme Court of Canada has confirmed that methods of medical treatment are not patentable subject matter under the Patent Act but has held that dosing regimen patents that do not require a physician's professional skill and judgment to implement remain valid. Fiona Legere of Blake, Cassels & Graydon LLP regards the decision as "the leading authority on the patentability of methods of medical treatment in Canada" – the court's "first ruling on substantive patent law in nearly a decade," she says, noting that it "brings much-needed clarity to the scope of patent protection for treatment-related innovations such as dosing regimens." The case centres on Janssen Inc.'s patent for dosing regimens for a long-acting inject- able formulation of paliperidone palmi- tate, a drug used to treat schizophrenia. The patent specifies fixed doses – 150 and 100 mg-eq. for the first and second doses, then 75 mg-eq. monthly – administered in designated muscle sites at set intervals, with a separate regimen for patients with impaired kidney function. Pharmascience Inc., seeking approval to market a generic version, challenged the patent as invalid on the basis that it impermissibly claims a method of medical treatment. Writing for a 7-2 majority, Justice Jamal grounded the exclusion in the broader prin- ciple that "professional skills – which are unrelated to trade, industry, or commerce" – fall outside the definition of "invention" in s. 2 of the Patent Act. Physicians already benefit from "a state-granted monopoly to practise and share their skills for the public benefit" and do not require patent protec- tion as an additional incentive, the SCC held. However, the majority also held that Janssen's dosing regimen patent does not impermissibly claim a method of medical treatment, because implementing the fixed dosing schedules does not require a physi- cian's professional skill and judgment after a treatment decision has been made. Justices O'Bonsawin and Moreau concurred in the result but disagreed with maintaining a blanket prohibition, arguing that the legal foundations of the exclusion have significantly eroded and that each claimed invention should be assessed on the same basis as any other. The SCC dismissed the appeal. The decision draws the line between patentable drug innovations and unpatentable medical practice. Andrew Brodkin, partner at Goodmans LLP, notes that "the holding is expected to influence how brand pharmaceutical companies draft patents in a way that complies with the stric- tures of the decision, and provide a basis to challenge the patentability of inventions that appear to tread on the professional judgment of medical practitioners." Marian Wolanski of Belmore Neidrauer LLP adds that "the decision will have direct conse- quences for pharmaceutical innovators, generic and biosimilar manufacturers, and the investors who fund them." Julie Desrosiers of Fasken Martineau DuMoulin LLP describes it as "the defining authority," adding that the decision "is expected to shape patent drafting and filing strategy, product life cycle management and phar- maceutical patent litigation across Canada's life sciences sector for years to come."

